Abstract
Since its discovery in the late 1990, small interfering RNA (siRNA) have quickly crept into the biopharmaceutical research as a new and powerful tool for the treatment of different human diseases based on altered gene-expression. Despite promising data from many pre-clinical studies, concrete hurdles still need to be overcome to bring therapeutic siRNAs in clinic. The design of stimuli-sensitive nanopreparations for gene therapy is a lively area of the current research. Compared to conventional systems for siRNA delivery, this type of platform can respond to local stimuli that are characteristics of the pathological area of interest, allowing the release of nucleic acids at the desired site. Acidic pH, de-regulated levels of enzymes, altered redox potential and magnetic field are examples of stimuli exploit to design stimuli-sensitive nanoparticles. In this review, we discuss on recent stimulisensitive strategies for siRNA delivery and we highlight on the potential of combining multiple stimuli-sensitive strategies in the same nano-platform for a better therapeutic outcome.
Keywords: Stimuli-sensitivity, nanoparticles, siRNA delivery, PEGylated nano-systems, combined therapy, multifunctional nanoparticles.
Current Pharmaceutical Design
Title:siRNA Delivery by Stimuli-Sensitive Nanocarriers
Volume: 21 Issue: 31
Author(s): Giuseppina Salzano, Daniel F. Costa and Vladimir P. Torchilin
Affiliation:
Keywords: Stimuli-sensitivity, nanoparticles, siRNA delivery, PEGylated nano-systems, combined therapy, multifunctional nanoparticles.
Abstract: Since its discovery in the late 1990, small interfering RNA (siRNA) have quickly crept into the biopharmaceutical research as a new and powerful tool for the treatment of different human diseases based on altered gene-expression. Despite promising data from many pre-clinical studies, concrete hurdles still need to be overcome to bring therapeutic siRNAs in clinic. The design of stimuli-sensitive nanopreparations for gene therapy is a lively area of the current research. Compared to conventional systems for siRNA delivery, this type of platform can respond to local stimuli that are characteristics of the pathological area of interest, allowing the release of nucleic acids at the desired site. Acidic pH, de-regulated levels of enzymes, altered redox potential and magnetic field are examples of stimuli exploit to design stimuli-sensitive nanoparticles. In this review, we discuss on recent stimulisensitive strategies for siRNA delivery and we highlight on the potential of combining multiple stimuli-sensitive strategies in the same nano-platform for a better therapeutic outcome.
Export Options
About this article
Cite this article as:
Salzano Giuseppina, Costa F. Daniel and Torchilin P. Vladimir, siRNA Delivery by Stimuli-Sensitive Nanocarriers, Current Pharmaceutical Design 2015; 21 (31) . https://dx.doi.org/10.2174/138161282131151013190410
DOI https://dx.doi.org/10.2174/138161282131151013190410 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antidepressant Desipramine Leads to C6 Glioma Cell Autophagy: Implication for the Adjuvant Therapy of Cancer
Anti-Cancer Agents in Medicinal Chemistry TRPM6 and TRPM7: A Mul-TRP-PLIK-Cation of Channel Functions
Current Pharmaceutical Biotechnology Novel Systemic Markers for Patients with Alzheimer Disease? – A Pilot Study
Current Alzheimer Research Establishing Genomic/Transcriptomic Links Between Alzheimer’s Disease and Type 2 Diabetes Mellitus by Meta-Analysis Approach
CNS & Neurological Disorders - Drug Targets Pharmacological Activation of LXRs Decreases Amyloid-β Levels in Niemann-Pick Type C Model Cells
Current Pharmaceutical Biotechnology The Tachykinergic System as Avenues for Drug Intervention
Recent Patents on CNS Drug Discovery (Discontinued) Lipid Nanoparticles for the Delivery of Biopharmaceuticals
Current Pharmaceutical Biotechnology Nuclear Medicine: Proof of Principle for Targeted Drugs in Diagnosis and Therapy
Current Pharmaceutical Design MicroRNAs Involved in Oxidative Stress Processes Regulating Physiological and Pathological Responses
MicroRNA Interferon-γ-Induced Neurotoxicity of Human Astrocytes
CNS & Neurological Disorders - Drug Targets Embryonic Morphogenetic Field Induces Phenotypic Reversion in Cancer Cells. Review Article
Current Pharmaceutical Biotechnology Are Retinoids a Promise for Alzheimer’s Disease Management?
Current Medicinal Chemistry PLK1 Inhibition: Prospective Role for the Treatment of Pediatric Tumors
Current Drug Targets Endocannabinoids and Their Receptors: Physiology, Pathology and Pharmacology
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) A Prooxidant Mechanism for the Anticancer and Chemopreventive Properties of Plant Polyphenols
Current Drug Targets Erythropoietin Signaling and Neuroprotection
Current Signal Transduction Therapy Exploiting Protein Phosphatase Inhibitors Based on Cantharidin Analogues for Cancer Drug Discovery
Mini-Reviews in Medicinal Chemistry Iron Chelators: Development of Novel Compounds with High and Selective Anti-Tumour Activity
Current Drug Delivery Polyphenols as Potential Inhibitors of Amyloid Aggregation and Toxicity:Possible Significance to Alzheimers Disease
Mini-Reviews in Medicinal Chemistry Biology of Protooncogene c-kit Receptor and Spermatogenesis
Current Pharmacogenomics